

ASX ANNOUNCEMENT

7 August 2020

**Respiri confirms commercial production of wheezos on track**

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, today provides an update on its manufacturing program.

As per Marjan Mikel’s presentation at the 26 May 2020 EGM Respiri was planning to manufacture and deliver its initial commercial volumes of wheezo devices during the period October through to December. The Company can today confirm that, despite the COVID-19 lockdown restrictions, manufacturing has commenced for the first batch of 3,000 wheezos. This batch is due for delivery in mid-October 2020 as scheduled.

The Company confirms that its manufacturing plans for CY 2021 also remain well on track.

Likewise preparations for a full scale commercial launch of wheezo are well underway and the planned launch in Q4 of calendar 2020 remains on schedule.

The Company would also like to advise that its preliminary full year results are due to be released on 25 August 2020.

Mr Mikel stated “It is testament to the dedication of the new team, commitment to executional excellence and the strong relationship that they maintain with our manufacturing partner that the Company has been able to forge ahead with its plans in these troubled times. It should also be noted that manufacturing of medical devices such as wheezo is classified as an essential service during the current pandemic. I look forward to commenting further on the launch plans once this initial batch has been delivered.”

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 7 August 2020 has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.